Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Predicting Japan Pharma in 2010: Pharma Delegate Seminar
June 6, 2005
- The Reporter's Eye: 9
June 6, 2005
- CMIC: Strong Growth in Semiannual Sales, Profits
June 6, 2005
- Toho Pharm.: Profits Plunge Despite 13.3% Rise in Sales
June 6, 2005
- Wyeth's Gemtuzumab Recommended for Approval
June 6, 2005
- Vital-Net Happy about Tie-up with Toho and Other Wholesalers
June 6, 2005
- Alfresa HD: Profits Slip Despite Growth in Sales
June 6, 2005
- Vfend and 8 Other Drugs Recommended for Approval
June 6, 2005
- Suzuken Aims for Domestic Market Share of 25% by 2010
June 6, 2005
- 18th INTERPHEX JAPAN
June 6, 2005
- BUSINESS NEWS IN BRIEF
May 30, 2005
- NEW PRODUCTS
May 30, 2005
- Flat Price System Is Unsuitable in Japan: Dr Okuda
May 30, 2005
- REGULATORY NEWS IN BRIEF
May 30, 2005
- Central, Local Gov't Must Cooperate Closely to Effectively Implement Amended PAL
May 30, 2005
- TPOICS
May 30, 2005
- Industry Appreciates Improvements Made by National Hospitals to Facilitate Clinical Trials
May 30, 2005
- Astellas Pharma: Sales of \862 Bil. in 1st Settlement
May 30, 2005
- R&D NEWS IN BRIEF
May 30, 2005
- Eisai: Aricept, Pariet Drive Growth in Sales, Profits
May 30, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…